View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 15, 2020

Moderna starts enrolment for high dose arm in Covid-19 vaccine trial

Moderna has begun enrolment of participants for the highest dose arm of a Phase I clinical trial assessing its mRNA-1273 vaccine candidate against Covid-19.

Moderna has begun enrolment of participants for the highest dose arm of a Phase I clinical trial assessing its mRNA-1273 vaccine candidate against Covid-19.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

Led by the US National Institutes of Health (NIH), the trial is designed to include arms for 25μg, 100μg and 250μg dose levels of mRNA-1273.

Initiated last month, the trial will recruit a total of 45 healthy adults aged 18 to 55.

Moderna also announced that the company is hosting its first Vaccine Day and reported positive interim data from Phase I study of its Zika vaccine candidate, mRNA-1893.

Dosing has been completed in all 10µg, 30µg, 100µg and 250µg cohorts in the Zika trial. An interim analysis reviewed safety and immunogenicity data from the 10µg and 30µg cohorts.

The 10µg and 30µg doses of mRNA-1893 were found to be generally well-tolerated, without any vaccine-related serious adverse events (SAEs) or adverse events of special interest (AESI), after two doses of vaccination given 28 days apart.

These dose levels also triggered a neutralising antibody response in participants who are flavivirus infection-naïve (seronegative) and those with pre-existing flavivirus antibodies (seropositive), said the company.

A single vaccination of the 30µg dose was observed to be enough to convert baseline flavivirus seronegative participants. The company further noted a clear benefit with a two-dose series given 28 days apart.

Moderna chief medical officer Tal Zaks said: “I am encouraged by these interim Phase I data showing the ability of mRNA-1893 to elicit a strong neutralising antibody response.

“Our Zika programme, along with our continued work on a vaccine candidate against the novel coronavirus, underscore our commitment to improving global public health through developing mRNA vaccines to prevent the spread of infectious diseases.”

According to the company, clinical data showed that its vaccine technology was generally well-tolerated and could induce durable immune responses against viral antigens.

Moderna CEO Stéphane Bancel added: “The totality of data from our vaccines platform gives us reason to be optimistic about the prospects for our vaccines to come, including our vaccine against the novel coronavirus.”

Currently, Moderna has nine prophylactic vaccine candidates in development.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena